论文部分内容阅读
目的:检测ABCC10在非小细胞肺癌(NSCLC)组织中的表达,探讨其与组织学类型、分级和TNM分期的关系,检测相应癌组织对化疗药物的敏感性。方法:采用免疫组化EnVin-sion法检测ABCC10在75例NSCLC组织中的表达,进行统计学分析。采用MTT法检测相应癌组织对化疗药物的敏感性,分析其与ABCC10表达的相关性。结果:ABCC10主要定位于胞膜上和胞质中。鳞癌、腺癌阳性率分别为77.5%和85.7%,两者差异有统计学意义,P=0.007。鳞癌、腺癌不同病理分级、TNM分期间ABCC10表达差异均有统计学意义(P=0.000、0.003、0.009和0.032)。NSCLC组织的耐药性试验结果与其相应组织中ABCC10的表达做相关性检验,多西他赛、紫杉醇、长春瑞滨、长春新碱、顺铂差异有统计学意义(P=0.000),相关系数分别为0.674、0.633、0.610、0.565和0.532。结论:ABCC10在NSCLC组织中高表达,其中腺癌表达高于鳞癌,表达的高低与组织学类型、分级,TNM分期有关,很可能与NSCLC化疗药物耐药有关。
OBJECTIVE: To detect the expression of ABCC10 in non-small cell lung cancer (NSCLC) tissues and to investigate its relationship with histological type, grading and TNM staging and to detect the sensitivity of corresponding cancer tissues to chemotherapeutic drugs. Methods: Immunohistochemical EnVin-sion method was used to detect the expression of ABCC10 in 75 cases of NSCLC tissues for statistical analysis. The sensitivity of chemotherapeutic drugs to corresponding cancer tissues was detected by MTT assay, and its correlation with ABCC10 expression was analyzed. Results: ABCC10 mainly located in the membrane and cytoplasm. The positive rates of squamous cell carcinoma and adenocarcinoma were 77.5% and 85.7% respectively, with a significant difference between them (P = 0.007). There were significant differences in the expression of ABCC10 between squamous cell carcinoma and adenocarcinoma under different TNM stages (P = 0.000, 0.003, 0.009 and 0.032). The drug resistance test results of NSCLC tissues were correlated with the expression of ABCC10 in the corresponding tissues. There was significant difference between docetaxel, paclitaxel, vinorelbine, vincristine and cisplatin (P = 0.000), the correlation coefficient Respectively 0.674, 0.633, 0.610, 0.565 and 0.532. CONCLUSION: ABCC10 is highly expressed in NSCLC tissues. The expression of ABCC10 in squamous cell carcinoma is higher than that in squamous cell carcinoma. The expression of ABCC10 is related to histological type, grade and TNM stage, which may be related to drug resistance in NSCLC.